Crucell

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Crucell N.V.
Type Privately held naamloze vennootschap; subsidiary
Industry Biotechnology
Founded 2000
Headquarters Leiden, Netherlands
Key people Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board)
Products Vaccines and antibodies
Revenue 329.8 million (2010)[1]
Operating income Decrease (€34.3 million) (2010)[1]
Profit Decrease (€27.6 million) (2010)[1]
Total assets €967.1 million (end 2010)[1]
Total equity €786.4 million (end 2010)[1]
Owner(s) Johnson & Johnson
Employees 1,250 (2009)[2]
Website www.crucell.com

Crucell is a biotechnology company specializing in vaccines and antibodies. The firm, a subsidiary of Johnson & Johnson, is headquartered in Leiden, Netherlands. Crucell shares were previously listed on the Euronext Amsterdam exchange and formed part of the AMX index until April 2011, when J&J completed a tender offer for the company.

History[edit]

In 1993 Introgene, Crucell’s predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.

In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.

On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.

On 28 September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[3] This follows in the wake of Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J agreed to acquire the rest of the company in October 2010, taking its stake to over 95% by February 2011[4] and delisting the company from stock exchanges two months later.[5]

Vaccine products[edit]

Paediatric[edit]

  • Quinvaxem
  • Hepavax-Gene
  • MoRu-Viraten
  • Epaxal-Junior

Travel and endemic[edit]

Respiratory[edit]

  • Inflexal V

References[edit]

  1. ^ a b c d e "Annual Results 2010". Crucell. Retrieved 27 February 2011. 
  2. ^ "Annual Report 2009". Crucell. Retrieved 2010-05-23. 
  3. ^ Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. Retrieved 28 September 2009. 
  4. ^ Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. Retrieved 27 February 2011. 
  5. ^ Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. Retrieved 16 April 2011. 

External links[edit]